134 related articles for article (PubMed ID: 21467125)
1. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).
Jantunen E; Canals C; Attal M; Thomson K; Milpied N; Buzyn A; Ferrant A; Biron P; Crawley C; Schattenberg A; Luan JJ; Tilly H; Rio B; Wijermans PW; Dreger P; Sureda A
Ann Oncol; 2012 Jan; 23(1):166-171. PubMed ID: 21467125
[TBL] [Abstract][Full Text] [Related]
2. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).
Dietrich S; Boumendil A; Finel H; Avivi I; Volin L; Cornelissen J; Jarosinska RJ; Schmid C; Finke J; Stevens WB; Schouten HC; Kaufmann M; Sebban C; Trneny M; Kobbe G; Fornecker LM; Schetelig J; Kanfer E; Heinicke T; Pfreundschuh M; Diez-Martin JL; Bordessoule D; Robinson S; Dreger P
Ann Oncol; 2014 May; 25(5):1053-8. PubMed ID: 24585719
[TBL] [Abstract][Full Text] [Related]
3. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Dreyling M; Lenz G; Hoster E; Van Hoof A; Gisselbrecht C; Schmits R; Metzner B; Truemper L; Reiser M; Steinhauer H; Boiron JM; Boogaerts MA; Aldaoud A; Silingardi V; Kluin-Nelemans HC; Hasford J; Parwaresch R; Unterhalt M; Hiddemann W
Blood; 2005 Apr; 105(7):2677-84. PubMed ID: 15591112
[TBL] [Abstract][Full Text] [Related]
4. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
5. The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis.
Wullenkord R; Berning P; Niemann AL; Wethmar K; Bergmann S; Lutz M; Schliemann C; Mesters R; Keßler T; Schmitz N; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2021 Nov; 100(11):2733-2744. PubMed ID: 34477953
[TBL] [Abstract][Full Text] [Related]
6. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
7. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.
Dahi PB; Tamari R; Devlin SM; Maloy M; Bhatt V; Scordo M; Goldberg J; Zelenetz AD; Hamlin PA; Matasar MJ; Maragulia J; Giralt SA; Perales MA; Moskowitz CH; Sauter CS
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2004-9. PubMed ID: 25175794
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 24563925
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.
Touzeau C; Leux C; Bouabdallah R; Roussel M; Delarue R; Bouabdallah K; Thieblemont C; Cacheux V; Cartron G; Compain L; Gyan E; Morschhauser F; Casasnovas O; Moles MP; Michallet AS; Gressin R; Damaj G; Rose C; Sirvent A; Hermine O; Mohty M; Milpied N; Le Gouill S
Ann Hematol; 2014 Feb; 93(2):233-42. PubMed ID: 23949376
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Kyriakou C; Canals C; Sibon D; Cahn JY; Kazmi M; Arcese W; Kolbe K; Gorin NC; Thomson K; Milpied N; Niederwieser D; Indrák K; Corradini P; Sureda A; Schmitz N
J Clin Oncol; 2010 May; 28(13):2227-32. PubMed ID: 20368570
[TBL] [Abstract][Full Text] [Related]
13. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.
Chakhachiro ZI; Saliba RM; Okoroji GJ; Korbling M; Alousi AM; Betul O; Anderlini P; Ciurea SO; Popat U; Champlin R; Samuels BI; Medeiros LJ; Bueso-Ramos C; Khouri IF
Cancer; 2013 Sep; 119(18):3318-25. PubMed ID: 23775587
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation (ASCT) in patients with mantle cell lymphoma: a retrospective study of the Spanish lymphoma group (GELTAMO).
García-Noblejas A; Cannata-Ortiz J; Conde E; González Barca E; Gutiérrez N; Rojas R; Vidal MJ; Ramírez MJ; Jiménez-Ubieto A; García-Ruiz JC; Sancho JM; López A; Ríos Rull P; Novelli S; Albo C; Debén G; López-Guillermo A; Nicolás C; González de Villambrosia S; Mercadal S; Martín García-Sancho A; Arranz R
Ann Hematol; 2017 Aug; 96(8):1323-1330. PubMed ID: 28536895
[TBL] [Abstract][Full Text] [Related]
15. CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma.
Berger MD; Branger G; Leibundgut K; Baerlocher GM; Seipel K; Mueller BU; Gregor M; Ruefer A; Pabst T
Leuk Res; 2015 Jun; 39(6):561-7. PubMed ID: 25890431
[TBL] [Abstract][Full Text] [Related]
16. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
Noring K; Carlsten M; Sonnevi K; Wahlin BE
BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
[TBL] [Abstract][Full Text] [Related]
17. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
[TBL] [Abstract][Full Text] [Related]
18. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP
J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Müller TH; Casper J; Kimmich C; Köhne CH; Petershofen E; Renzelmann A; Thole R; Voss A; Dreyling M; Hoster E; Klapper W; Pott C
Eur J Haematol; 2023 Aug; 111(2):220-228. PubMed ID: 37094812
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galego A; Jiménez JL; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Coria E; Rodriguez A; Martín A; López-Guillermo A; Salar A; Lahuerta JJ;
Cancer Med; 2017 Dec; 6(12):2766-2774. PubMed ID: 29076254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
